MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer

Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations

(2015) Ludovica Ciuffreda et al.   NEOPLASIA

DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance

(2015) Euan A. Stronach et al.   NEOPLASIA

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

KRAS and MAPK1 Gene Amplification in Type II Ovarian Carcinomas

(2013) Mohammed Rahman et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

MEK and the inhibitors: from bench to bedside

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance

(2012) Edita Aksamitiene et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients

(2012) Balázs Győrffy et al.   ENDOCRINE-RELATED CANCER

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

(2012) John Farley et al.   LANCET ONCOLOGY

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Jetset: selecting the optimal microarray probe set to represent a gene

(2011) Qiyuan Li et al.   BMC BIOINFORMATICS

Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer

(2011) Peter D. Boasberg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples

(2011) Tibor Fekete et al.   INTERNATIONAL JOURNAL OF CANCER

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance

(2011) W Li et al.   ONCOGENE

Molecular mechanisms of cisplatin resistance

(2011) L Galluzzi et al.   ONCOGENE

MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells In vitro and In vivo

(2010) Y. C. Henderson et al.   MOLECULAR CANCER THERAPEUTICS

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

(2009) David M. Gershenson et al.   GYNECOLOGIC ONCOLOGY

Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group

(2009) David S. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

A prognostic gene expression index in ovarian cancer-validation across different independent data sets

(2009) Carsten Denkert et al.   JOURNAL OF PATHOLOGY

A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma

(2008) B. GYÖRFFY et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Gene-expression profiling in epithelial ovarian cancer

(2008) Panagiotis A Konstantinopoulos et al.   Nature clinical practice. Oncology